Essilor: Result of the payment of dividends in shares and record of the corresponding capital increase

Charenton Cedex, FRANCE


Result of the payment of dividends in shares
and record of the corresponding capital increase

Charenton-le-Pont, France (June 3, 2016 - 6.00 p.m.) - The General Meeting of Essilor International has decided to grant to the shareholders the option to receive their dividend in shares.

The price for newly issued shares for the payment of the dividend is set at €100.08 per share. This price corresponds to 90% of the average of the opening prices quoted on Euronext Paris over the twenty trading days preceding the date of the General Annual Meeting less the net dividend, rounded up to the nearest euro cent.

The period to opt for payment of the dividend in newly issued shares was open from May 17, 2016 up to, and including, May 30, 2016. At the end of the option period, 67.61% of rights were exercised in favor of the 2015 dividend payment in shares.

For the purposes of the dividend payment in shares, 1,578,804 new shares will be issued, representing 0.73% of Essilor's share capital on the basis of the share capital as of May 16, 2016.

The settlement and delivery of the shares as well as their admission to trading on Euronext Paris will occur on Wednesday June 8, 2016. The shares will carry dividend rights as from January 1, 2016 and will be fully assimilated to existing shares already listed.

The total cash dividend to be paid to the shareholders who did not choose the share option amounts to € 76,817,314.68 and will be paid from Wednesday June 8, 2016 onwards.

About Essilor
The world's leading ophthalmic optics company, Essilor designs, manufactures and markets a wide range of lenses to improve and protect eyesight. Its mission is to improve lives by improving sight. To support this mission, Essilor allocates more than €200 million to research and innovation every year, in a commitment to continuously bring new, more effective products to market. Its flagship brands are Varilux®, Crizal®, Transitions®, Eyezen(TM), Xperio®, Foster Grant®, Bolon(TM) and Costa®. It also develops and markets equipment, instruments and services for eyecare professionals.
Essilor reported consolidated revenue of more than €6.7 billion in 2015 and employs 61,000 people worldwide. It markets its products in more than 100 countries and has 32 plants, 490 prescription laboratories and edging facilities, as well as five research and development centers around the world. For more information, please visit www.essilor.com.
The Essilor share trades on the Euronext Paris market and is included in the Euro Stoxx 50 and CAC 40 indices.  
Codes and symbols: ISIN: FR0000121667; Reuters: ESSI.PA; Bloomberg: EI:FP.

CONTACTS

Investor Relations
Véronique Gillet - Sébastien Leroy
Ariel Bauer
Tel.: +33 (0)1 49 77 42 16
Corporate Communications
Lucia Dumas
Tel.: +33 (0)1 49 77 45 02
Media Relations
Maïlis Thiercelin
Tel.: +33 (0)1 49 77 45 02

Attachments

PDF Version of the news release